ChiCTR2300071154 版本V1.0 版本创建时间2023/05/06 11:18:40 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2300071154 

最近更新日期:

Date of Last Refreshed on:

2023-05-06 11:18:35 

注册时间:

Date of Registration:

2023-05-06 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

基于两种方法指导的精准肺保护性通气策略对腹腔热灌注化疗术患者术中呼吸功能及术后肺部并发症的影响

Public title:

Effect of precision lung protective ventilation strategy guided by two methods on intraoperative respiratory function and postoperative pulmonary complications in patients undergoing peritoneal thermoperfusion chemotherapy

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于两种方法指导的精准肺保护性通气策略对腹腔热灌注化疗术患者术中呼吸功能及术后肺部并发症的影响

Scientific title:

Effect of precision lung protective ventilation strategy guided by two methods on intraoperative respiratory function and postoperative pulmonary complications in patients undergoing peritoneal thermoperfusion chemotherapy

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

肖莉 

研究负责人:

肖莉 

Applicant:

Li Xiao 

Study leader:

Li Xiao 

申请注册联系人电话:

Applicant telephone:

+86 10 63926501

研究负责人电话:

Study leader's telephone:

+86 10 63926501

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

lxfn5563368@126.com

研究负责人电子邮件:

Study leader's E-mail:

lxfn5563368@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

北京市海淀区羊坊店铁医路10号

研究负责人通讯地址:

北京市海淀区羊坊店铁医路10号

Applicant address:

10 Tieyi Road, Yangfangdian, Haidian District, Beijing City, China

Study leader's address:

10 Tieyi Road, Yangfangdian, Haidian District, Beijing City, China

申请注册联系人邮政编码:

Applicant postcode:

100038

研究负责人邮政编码:

Study leader's postcode:

100038

申请人所在单位:

首都医科大学附属北京世纪坛医院

Applicant's institution:

Beijing Shijitan Hospital, Capital Medical University

研究负责人所在单位:

首都医科大学附属北京世纪坛医院

Affiliation of the Leader:

Beijing Shijitan Hospital, Capital Medical University

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

sjtkyll-lx-2023(48)

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

首都医科大学附属北京世纪坛医院科学伦理委员会

Name of the ethic committee:

Science Ethics Committee of Beijing Shijitan Hospital ,Capital Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2023-03-01 00:00:00

伦理委员会联系人:

李继红

Contact Name of the ethic committee:

Jihong Li

伦理委员会联系地址:

北京市海淀区羊坊店铁医路10号

Contact Address of the ethic committee:

10 Tieyi Road, Yangfangdian, Haidian District, Beijing City, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 10 63926603

伦理委员会联系人邮箱:

Contact email of the ethic committee:

sjtkyll@126.com

研究实施负责(组长)单位:

首都医科大学附属北京世纪坛医院

Primary sponsor:

Beijing Shijitan Hospital, Capital Medical University

研究实施负责(组长)单位地址:

北京市海淀区羊坊店铁医路10号

Primary sponsor's address:

10 Tieyi Road, Yangfangdian, Haidian District, Beijing City, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

海淀区

Country:

China

Province:

Beijing

City:

Haidian District

单位(医院):

首都医科大学附属北京世纪坛医院

具体地址:

北京市海淀区羊坊店铁医路10号

Institution
hospital:

Beijing Shijitan Hospital, Capital Medical University

Address:

10 Tieyi Road, Yangfangdian, Haidian District, Beijing City, China

经费或物资来源:

2022年院青年基金

Source(s) of funding:

2022 Hospital youth fund

Target disease:

phymatology

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

驱动压为潮气量与呼吸系统顺应性的比值,驱动压越低,顺应性越高,可有效避免肺不张和肺过度膨胀。有学者用最小ΔP 滴定最佳 PEEP,发现该方法可降低 PPCs 的发生率。驱动压法优点是简便易行,缺点是粗略、不精确。 电阻抗断层成像(Electrical Impedance Tomography,EIT)技术是近年来应用于ICU等场景的床旁监测方法,具有实时监测、无辐射、无创、功能成像等优点,可用于动态监测并指导机械通气的实施过程,滴定个体化PEEP,从而做到精准肺保护性通气。我们希望可以帮助监测CRS+HIPEC患者术中通气功能及降低患者术后肺部并发症的目的。EIT法的优点是实时、准确,缺点是复杂需要特定设备。 本研究旨在对比应用EIT技术和驱动压法指导HIPEC患者术中iPEEP的滴定,确定更好的肺保护通气策略,以实现精准肺保护,最大程度的改善通气,减少死腔率和肺血分流率,改善肺动态顺应性,减少肺不张的发生,以达到降低术后肺部并发症,缩短平均住院日的目的。  

Objectives of Study:

The driving pressure is the ratio of tidal volume to the compliance of respiratory system. The lower the driving pressure, the higher the compliance, which can effectively avoid attrition and hyperinflation of lung. The optimal PEEP was titrated with minimum ΔP and found to reduce the incidence of PPCs. The advantages of driving pressure method are simple and easy to operate, but the disadvantages are rough and inaccurate. Electrical Impedance Tomography (EIT) technology is a bed side monitoring method applied in ICU and other scenarios in recent years. It has the advantages of real-time monitoring, non-radiation, non-invasive, functional imaging, etc. It can be used for dynamic monitoring and guiding the implementation process of mechanical ventilation and titrating individualized PEEP. To achieve accurate lung protective ventilation. We hope to help monitor intraoperative ventilation function and reduce postoperative pulmonary complications in patients with CRS+HIPEC. The advantages of EIT method are real-time and accurate, but the disadvantages are complex and require specific equipment. The purpose of this study was to compare the application of EIT technology and driving pressure method to guide the titration of iPEEP in HIPEC patients during the operation, so as to determine a better lung protective ventilation strategy, so as to achieve accurate lung protection, improve ventilation to the maximum extent, reduce the rate of dead space and pulmonary blood circulation, improve lung dynamic compliance, reduce the occurrence of atelectasis, and reduce postoperative lung complications. The purpose of shortening the average length of stay.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

择期行肿瘤细胞减灭术联合腹腔热灌注化疗术患者,无性别限制,年龄<80周岁,>18周岁

Inclusion criteria

The patients, aged <80 years and >18 years, were selected to receive tumor cell reduction combined with intraperitoneal thermoperfusion chemotherapy without gender limitation

排除标准:

①体重指数(body mass index,BMI )> 30 kg/m2; ②正在患有急性或慢性的呼吸道疾病; ③术前已存在中、大量胸腔积液者; ④近14天内服用过β2受体激动剂、异丙托溴胺气雾剂、糖皮质激素或者茶碱类及其衍生物等用药史; ⑤体内安装有植入式心脏除颤器、心脏起搏器及其他有电活动的植入物者; ⑥严重的心肺功能障碍者; ⑦血流动力学严重不稳者、重度恶病质营养不良者。

Exclusion criteria:

① body mass index (BMI) > 30 kg/m2; ② is suffering from acute or chronic respiratory disease; ③ Patients with moderate or large amount of pleural effusion before surgery; ④ History of taking β2 receptor agonists, ipratropium bromide aerosol, glucocorticoids or theophylline and its derivatives within the past 14 days; (5) Patients with implantable cardiac defibrillators, pacemakers and other implants with electrical activity; ⑥ serious cardiopulmonary dysfunction; ⑦ Severe hemodynamic instability, severe cachexia malnutrition.

研究实施时间:

Study execute time:

From 2023-06-01 00:00:00 To 2025-05-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2023-06-01 00:00:00 To 2025-05-31 00:00:00  

干预措施:

Interventions:

组别:

A组(驱动压组)

样本量:

45

Group:

A Group

Sample size:

干预措施:

驱动压法滴定PEEP

干预措施代码:

Intervention:

PEEP was titrated by driving pressure

Intervention code:

组别:

B组(EIT)组

样本量:

45

Group:

B group

Sample size:

干预措施:

EIT法滴定个体化PEEP

干预措施代码:

Intervention:

EIT method titrates individual PEEP

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京市 

市(区县):

海淀区 

Country:

China 

Province:

Beijing 

City:

Haidin District 

单位(医院):

首都医科大学附属北京世纪坛医院 

单位级别:

三级甲等 

Institution
hospital:

Beijing Shijitan Hospital, Capital Medical University

Level of the institution:

IIIa

测量指标:

Outcomes:

指标中文名:

肿瘤坏死因子-a

指标类型:

次要指标

Outcome:

TNF-a

Type:

Secondary indicator

测量时间点:

手术前和手术结束时

测量方法:

化学发光免疫分析技术

Measure time point of outcome:

Before the operation;At the end of the operation

Measure method:

Chemiluminescence immunoassay

指标中文名:

白介素-6

指标类型:

次要指标

Outcome:

IL-6

Type:

Secondary indicator

测量时间点:

手术前和手术结束时

测量方法:

酶联免疫吸附试验

Measure time point of outcome:

Before the operation;At the end of the operation

Measure method:

enzyme linked immunosorbent assay

指标中文名:

随访术后肺部并发症发生情况

指标类型:

主要指标

Outcome:

Postoperative pulmonary complications were followed up

Type:

Primary indicator

测量时间点:

术后7天之内

测量方法:

随访观察

Measure time point of outcome:

Within 7 days after surgery

Measure method:

follow-up observation

指标中文名:

平均住院日

指标类型:

主要指标

Outcome:

average length of stay

Type:

Primary indicator

测量时间点:

出院时

测量方法:

病案室

Measure time point of outcome:

Measure method:

指标中文名:

个体化PEEP

指标类型:

次要指标

Outcome:

iPEEP

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

呼吸参数指标(Ppeak、Pplat、Pmean、Cdyn、PO2、氧合指数、分流率、死腔率)

指标类型:

次要指标

Outcome:

Respiratory parameters (Ppeak, Pplat, Pmean, Cdyn, PO2, oxygenation index, fractional flow rate, dead cavity rate)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

iPEEP水平与术后肺部并发症的相关性

指标类型:

次要指标

Outcome:

Association of iPEEP levels with postoperative pulmonary complications

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

简单随机

Randomization Procedure (please state who generates the random number sequence and by what method):

simple randomization

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

单盲:对受试者隐藏分组,对研究者不隐藏分组

Blinding:

Single-blind: Groups are hidden from subjects and not from researchers

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

2026年5月 本网站

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

May 2026 This website

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据采集:采用病例记录表 数据管理:电子采集和管理系统(Electronic Data Capture, EDC)

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data collection: Case records were used Data management: Electronic Data Capture and Management System (EDC)

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2023-05-06 11:18:35